Literature DB >> 26055227

Paliperidone Protects SH-SY5Y Cells Against MK-801-Induced Neuronal Damage Through Inhibition of Ca(2+) Influx and Regulation of SIRT1/miR-134 Signal Pathway.

Dexiao Zhu1, Jing Zhang1, Jintao Wu1, Guibao Li1, Wei Yao2, Jing Hao3, Jinhao Sun4.   

Abstract

Schizophrenia is a serious psychotic disease. Recently, increasing evidences support that neurodegeneration occurs in the brain of schizophrenia patients with progressive morphological changes. Paliperidone, an atypical antipsychotic drug, could attenuate psychotic symptom and protect neurons from different stressors. However, the underlying mechanisms are largely unknown. In this study, we used SH-SY5Y cells to evaluate the neuroprotective capability of paliperidone against the neurotoxicity induced by N-methyl-D-aspartate receptor antagonist, MK-801. And, we also explored the possible molecular mechanism. Neurotoxicity of 100 μM MK-801, which reduced the cell viability, was diminished by 100 μM paliperidone using MTT and LDH assays (both p < 0.05). Analysis with Hoechst 33342/PI double staining demonstrated that exposure to MK-801 (100 μM) for 24 h led to the death of 30 % of cultured cells (p < 0.05). Moreover, the patch clamp technique was employed to detect voltage calcium channel changes; the results showed that paliperidone effectively blocked the Ca(2+) influx through inhibiting the voltage-gated calcium channels (p < 0.05). Furthermore, paliperidone significantly reversed MK-801 induced increase of SIRT1 and decrease of miR-134 expression (both p < 0.05). Finally, SIRT1 inhibitor nicotinamide blocked MK-801 injury effects and suppressed miR-134 expression. Taken together, our results demonstrated that paliperidone could protect SH-SY5Y cells against MK-801 induced neurotoxicity via inhibition of Ca(2+) influx and regulation of SIRT1/miR-134 pathway, providing a promising and potential therapeutic target for schizophrenia.

Entities:  

Keywords:  MK-801; Neuroprotection; Paliperidone; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26055227     DOI: 10.1007/s12035-015-9217-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  45 in total

Review 1.  Ca2+ signals and death programmes in neurons.

Authors:  Laura Berliocchi; Daniele Bano; Pierluigi Nicotera
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

2.  SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons.

Authors:  Ying Li; Wei Xu; Michael W McBurney; Valter D Longo
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

Review 3.  MicroRNA function and neurotrophin BDNF.

Authors:  Tadahiro Numakawa; Misty Richards; Naoki Adachi; Soichiro Kishi; Hiroshi Kunugi; Kazuo Hashido
Journal:  Neurochem Int       Date:  2011-06-24       Impact factor: 3.921

4.  Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement.

Authors:  Kyoung-Sae Na; Chul-Eung Kim; Yong-Sik Kim; Jong-Il Lee; Wou Sang Han; Ung Gu Kang; Doo-Heum Park; Bongseog Kim; Han-Yong Jung; Jin-Sang Yoon; Se-Won Lim
Journal:  Hum Psychopharmacol       Date:  2013-02-18       Impact factor: 1.672

5.  Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

Authors:  Jennifer Kern Sliwa; Cynthia A Bossie; Yi-Wen Ma; Larry Alphs
Journal:  Schizophr Res       Date:  2011-07-20       Impact factor: 4.939

6.  Increased phosphorylation of Ser473-Akt, Ser9-GSK-3beta and Ser133-CREB in the rat frontal cortex after MK-801 intraperitoneal injection.

Authors:  Yong Min Ahn; Myoung Suk Seo; Se Hyun Kim; Yeni Kim; Se Chang Yoon; Yong-Sung Juhnn; Yong Sik Kim
Journal:  Int J Neuropsychopharmacol       Date:  2005-05-09       Impact factor: 5.176

Review 7.  Brain activation of SIRT1: role in neuropathology.

Authors:  Alanna Fernandes Paraíso; Keila Lopes Mendes; Sergio Henrique Sousa Santos
Journal:  Mol Neurobiol       Date:  2013-04-25       Impact factor: 5.590

8.  Genetic association of sirtuin genes and Parkinson's disease.

Authors:  Silvia Jesús; Pilar Gómez-Garre; Fátima Carrillo; María T Cáceres-Redondo; Ismael Huertas-Fernández; Inmaculada Bernal-Bernal; Marta Bonilla-Toribio; Laura Vargas-González; Manuel Carballo; Pablo Mir
Journal:  J Neurol       Date:  2013-05-30       Impact factor: 4.849

Review 9.  Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies.

Authors:  A Vita; L De Peri; G Deste; E Sacchetti
Journal:  Transl Psychiatry       Date:  2012-11-20       Impact factor: 6.222

Review 10.  Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.

Authors:  Siddharth Sarkar; Sandeep Grover
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

View more
  10 in total

1.  Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells.

Authors:  Gabriela Maciel Vieira; Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Bradley J Smith
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients.

Authors:  Natalia Rodríguez; Patricia Gassó; Albert Martínez-Pinteño; Àlex-González Segura; Gisela Mezquida; Lucia Moreno-Izco; Javier González-Peñas; Iñaki Zorrilla; Marta Martin; Roberto Rodriguez-Jimenez; Iluminada Corripio; Salvador Sarró; Angela Ibáñez; Anna Butjosa; Fernando Contreras; Miquel Bioque; Manuel-Jesús Cuesta; Mara Parellada; Ana González-Pinto; Esther Berrocoso; Miquel Bernardo; Sergi Mas
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-27

3.  Nicotinamide improves in vitro lens regeneration in a mouse capsular bag model.

Authors:  Xiaomin Liu; Qingjun Zhou; Yusen Huang; Zheng Fan; Haoyun Duan; Menghan Wang; Zongyi Li; Lixin Xie
Journal:  Stem Cell Res Ther       Date:  2022-05-12       Impact factor: 8.079

4.  Paliperidone Compared with Haloperidol on the Theory of Mind Tasks in Schizophrenia: A Pilot Trial.

Authors:  Jie Zhong; Hong Zhu; Dongqing Yin; Yanzhe Ning; Sisi Zheng; Yanbo Zhang; Hongxiao Jia
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-14       Impact factor: 2.570

5.  Understanding Pharmaco-Epigenomic Response of Antipsychotic Drugs Using Genome-Wide MicroRNA Expression Profile in Liver Cell Line.

Authors:  Babu Swathy; Moinak Banerjee
Journal:  Front Mol Neurosci       Date:  2022-03-22       Impact factor: 5.639

6.  Effect of Haloperidol and Olanzapine on Hippocampal Cells' Proliferation in Animal Model of Schizophrenia.

Authors:  Jana Osacka; Alexander Kiss; Zuzana Bacova; Andrej Tillinger
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

7.  CACNA1C Gene rs1006737 Polymorphism Affects Cognitive Performance in Chinese Han Schizophrenia.

Authors:  Mengyi Chen; Qi Jiang; Lei Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-10       Impact factor: 2.989

8.  Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.

Authors:  Ilaria Cuomo; Georgios D Kotzalidis; Simone de Persis; Daria Piacentino; Filippo Perrini; Emanuela Amici; Sergio De Filippis
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-21       Impact factor: 2.570

9.  SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride.

Authors:  Qian Zhao; Zhiyuan Tian; Guoyu Zhou; Qiang Niu; Jingwen Chen; Pei Li; Lixin Dong; Tao Xia; Shun Zhang; Aiguo Wang
Journal:  Theranostics       Date:  2020-03-26       Impact factor: 11.556

Review 10.  In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia.

Authors:  Oliwia Koszła; Katarzyna M Targowska-Duda; Ewa Kędzierska; Agnieszka A Kaczor
Journal:  Biomolecules       Date:  2020-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.